Treatment with neuraminidase inhibitors for high-risk patients with influenza: Why is adherence to antiviral treatment recommendations so low?

Journal of Infectious Diseases

Volumn 210, Issue 4, 2014, Pages 510-513

  Lindegren, Mary Lou ^a   Schaffner, William ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antiviral treatment; Influenza

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FALSE NEGATIVE RESULT; HEALTH CARE ACCESS; HELP SEEKING BEHAVIOR; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; NAUSEA AND VOMITING; NOTE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SEASONAL INFLUENZA;

ADHERENCE; ANTIVIRAL TREATMENT; INFLUENZA;

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 84905592926     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu227     Document Type: Note

References (45)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-40.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86.
3. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54: 1427-36.
4. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-24.
5. Centers for Disease CaP. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season. http: // www.cdc.gov/h1n1flu/recommendations.htm. Accessed 17 April 2013.
6. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva, 2010.
7. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children- diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1003-32.
8. Biggerstaff M, Jhung MA, Reed C, et al. Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-2011 influenza season-United States. J Infect Dis 2014; 210: 535-44.
9. Biggerstaff M, Jhung MA, Reed C, et al. Impact of medical and behavioural factors on influenza-like illness, healthcare-seeking, and antiviral treatment during the 2009 H1N1 pandemic: USA, 2009-2010. Epidemiol Infect 2014; 142: 114-25.
10. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis 2011; 204: 1848-56.
11. Garg S, Chaves SS, Perez A, et al. Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic. Clin Infect Dis 2012; 55: e18-21.
12. Hernandez JE, Grainger J, Simonsen L, et al. Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment. Influenza Other Respi Viruses 2012; 6: 305-8.
13. Taylor G, Mitchell R, Fernandes R, et al. Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic. Antimicrob Resist Infect Control 2014; 3: 2.
14. Hersh AL, Stafford RS. Antiviral prescribing by office-based physicians during the 2009 H1N1 pandemic. Ann Intern Med 2011; 154: 74-6.
15. Williams LO, Kupka NJ, Schmaltz SP, et al. Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings preand post-2009 H1N1 pandemic. J Clin Virol 2014; 2014 Feb 12. pii: S1386-6532(14) 00036-5. doi: 10.1016/j.jcv.2014.01.016. [Epub ahead of print].
16. PetersTR, SuerkenCK, SnivelyBM, et al. Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011. Acad Emerg Med 2013; 20: 786-94.
17. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010; 50: 747-51.
18. Stein J, Louie J, Flanders S, et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. Ann Emerg Med 2005; 46: 412-9.
19. Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156: 500-11.
20. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis 2009; 48: e89-92.
21. Ayscue P, Murray E, Uyeki T, et al. Influenzaassociated intensive-care unit admissions and deaths-California, September 29, 2013- January 18, 2014. MMWR Morb Mortal Wkly Rep 2014; 63: 143-7.
22. Katz MA, Lamias MJ, Shay DK, et al. Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza Other Respi Viruses 2009; 3: 29-35.
23. Rothberg MB, Bonner AB, Rajab MH, et al. Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza. Clin Infect Dis 2006; 42: 95-9.
24. Michiels B, Van Puyenbroeck K, Verhoeven V, et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLOS One 2013; 8: e60348.
25. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1: CD008965.
26. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Systematic Rev 2012; 4: CD002744.
27. Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-265, iii-iv.
28. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53: 277-9.
29. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156: 512-24.
30. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and metaanalysis in hospitalized patients. J Infect Dis 2013; 207: 553-63.
31. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-204.
32. Louie JK, Yang S, Samuel MC, et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132: e1539-45.
33. Viasus D, Pano-Pardo JR, Pachon J, et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011; 140: 1025-32.
34. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202: 1154-60.
35. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568-75.
36. Lee BY, McGlone SM, Bailey RR, et al. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computermodeling.PLOSOne 2010; 5: e11284.
37. Talbird SE, Brogan AJ, Winiarski AP, et al. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm 2009; 66: 469-80.
38. You JH, Chan ES, Leung MY, et al. A costeffectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong. PLOS One 2012; 7: e33123.
39. Dugas AF, Coleman S, Gaydos CA, et al. Cost-utility of rapid polymerase chain reaction- based influenza testing for high-risk emergency department patients. Ann Emerg Med 2013; 62: 80-8.
40. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003; 139: 321-9.
41. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201: 1654-62.
42. Lovegrove MC, Shehab N, Hales CM, et al. Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic. Public Health Rep 2011; 126: 312-7.
43. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013; 56: 1197-205.
44. Tam K, Yousey-Hindes K, Hadler JL. Influenza-related hospitalization of adults associated with low census tract socioeconomic status and female sex in New Haven County, Connecticut, 2007-2011. Influenza Other Respi Viruses 2014; 8: 274-81.
45. Yousey-Hindes KM, Hadler JL. Neighborhood socioeconomic status and influenza hospitalizations among children: New Haven County, Connecticut, 2003-2010. AmJ Public Health 2011; 101: 1785-9.